Britain's cost watchdog on board with Biogen's Spinraza

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Britain's National Institute for Health and Care Excellence (NICE), the advisor to the National Health Service (NHS) on costs and care quality, has recommended routine access for Biogen's (NASDAQ:BIIB) SPINRAZA (nusinersen) for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.

Subscribe for full text news in your inbox